Author： Chim Lesley Kelly Patrick J. Salkeld Glenn Stockler Martin R.
Publisher： Adis International
ISSN： 1170-7690
Source： PharmacoEconomics, Vol.28, Iss.6, 2010-06, pp. : 463-475
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
BP programmes to prevent stroke worthwhile in Australia?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 649, 2012-01 ,pp. :
Access to resources
Recommend
SLNB or ALND for staging of EBC in Australia?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 651, 2012-01 ,pp. :
Aluminium in Over-the-Counter Drugs: Risks Outweigh Benefits?
By Reinke C.M.
Drug Safety, Vol. 26, Iss. 14, 2003-01 ,pp. :
Majority of recommended drugs achieve timely PBS listing
Inpharma, Vol. 1, Iss. 1558, 2006-01 ,pp. :
Is the UK government delaying approval for new cancer drugs?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 649, 2012-01 ,pp. :